doi:10.3969/j.issn.1004-583X.2025.12.015

Abstract

CLC Number:

R735.7

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.12.015

https://www.lchc.cn/EN/Y2025/V40/I12/1136

References 61

[1]	Llovet JM, Kelley RK, Villanueva A, et al. Author correction: Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2024, 10(1):10.doi: 10.1038/s41572-024-00500-6. pmid: 38346997
[2]	杨嘉睿, 江建新. 《2024年欧洲肝病学会临床实践指南:肝细胞癌管理》摘译[J]. 临床肝胆病杂志, 2025, 41(2): 234-239. doi:10.12449/JCH250207.
[3]	Kim J, DeBerardinis RJ. Mechanisms and implications of metabolic heterogeneity in cancer[J]. Cell Metab, 2019, 30(3): 434-446. doi: 10.1016/j.cmet.2019.08.013. pmid: 31484055
[4]	Ward PS, Thompson CB. Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate[J]. Cancer Cell, 2012, 21(3): 297-308. doi: 10.1016/j.ccr.2012.02.014. pmid: 22439925
[5]	Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation[J]. Science, 2009, 324(5930): 1029-1033. doi: 10.1126/science.1160809. pmid: 19460998
[6]	Li C, Chen J, Li Y, et al. 6-Phosphogluconolactonase promotes hepatocellular carcinogenesis by activating pentose phosphate pathway[J]. Front Cell Dev Biol, 2021, 9: 753196. doi: 10.3389/fcell.2021.753196.eCollection 2021.
[7]	Zhang J, Zhang Z, Wu Z, et al. The switch triggering the invasion process: Lipid metabolism in the metastasis of hepatocellular carcinoma[J]. Chin Med J (Engl), 2024, 137(11): 1271-1284. doi: 10.1097/CM9.0000000000003144. Epub 2024 May 13.
[8]	Wang J, Wang H, Gao M, et al. The regulation of amino acid metabolism in tumor cell death: From the perspective of physiological functions[J]. Apoptosis, 2023, 28(9-10): 1304-1314. doi: 10.1007/s10495-023-01875-9. Epub 2023 Jul 31.
[9]	Caini P, Carloni V. Metabolism and immune suppressive response in liver cancer[J]. Biomedicines, 2025, 13(6):1461. doi: 10.3390/biomedicines13061461.
[10]	Lan Q, Ouyang A, Chen Y, et al. Pain, lactate, and anesthetics: Intertwined regulators of tumor metabolism and immunity[J]. Front Oncol, 2025, 15: 1534300. doi: 10.3389/fonc.2025.1534300.eCollection2025.
[11]	夏宁, 刘丽华. 低氧诱导因子促进恶性肿瘤免疫逃逸的机制及其临床转化[J]. 中国肿瘤生物治疗杂志, 2021, 28(11): 1129-1134.doi: 10.3872/j.issn.1007-385x.2021.11.011.
[12]	Lee NCW, Carella MA, Papa S, et al. High expression of glycolytic genes in cirrhosis correlates with the risk of developing liver cancer[J]. Front Cell Dev Biol, 2018, 6: 138. doi: 10.3389/fcell.2018.00138. eCollection 2018. pmid: 30430110
[13]	Zhang C, Liu Z, Wang F, et al. Nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy based on NADPH depletion[J]. Drug Deliv, 2023, 30(1): 2162160. doi: 10.1080/10717544.2022.2162160.
[14]	Yin Q, Yao Y, Ni J, et al. DLAT activates EMT to promote HCC metastasis by regulating GLUT1-mediated aerobic glycolysis[J]. Mol Med, 2025, 31(1): 71. doi: 10.1186/s10020-025-01125-5. pmid: 39979835
[15]	He K, Tao F, Lu Y, et al. The role of HK2 in tumorigenesis and development: Potential for targeted therapy with natural products[J]. Int J Med Sci, 2025, 22(4): 790-805. doi: 10.7150/ijms.105553. eCollection 2025. pmid: 39991762
[16]	Yu T, Liu Z, Tao Q, et al. Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming[J]. Cancer Lett, 2024, 589: 216824. doi: 10.1016/j.canlet.2024.216824. Epub 2024 Mar 22.
[17]	Kam CS, Ho DW, Ming VS, et al. PFKFB4 drives the oncogenicity in TP53-mutated hepatocellular carcinoma in a phosphatase-dependent manner[J]. Cell Mol Gastroenterol Hepatol, 2023, 15(6): 1325-1350. doi: 10.1016/j.jcmgh.2023.02.004. pmid: 36806581
[18]	Yang W, Wang Y, Tao K, et al. Metabolite itaconate in host immunoregulation and defense[J]. Cell Mol Biol Lett, 2023, 28(1): 100. doi: 10.1186/s11658-023-00503-3. pmid: 38042791
[19]	Mahmoudvand S, Sheikhrobat SB, Shokri S, et al. From immunity to oncology: Itaconic acid as a driver in HBV-induced HCC[J]. J Cell Mol Med, 2025, 29(12): e70612. doi: 10.1111/jcmm.70612.
[20]	Li F, Wang B, Li H, et al. G6PD and machine learning algorithms as prognostic and diagnostic indicators of liver hepatocellular carcinoma[J]. BMC Cancer, 2024, 24(1): 157. doi: 10.1186/s12885-024-11887-6. pmid: 38297250
[21]	Zeng T, Li B, Shu X, et al. Pan-cancer analysis reveals that G6PD is a prognostic biomarker and therapeutic target for a variety of cancers[J]. Front Oncol, 2023, 13: 1183474. doi: 10.3389/fonc.2023.1183474. eCollection 2023.
[22]	Gu XY, Zhou ZJ, Yao H, et al. The role of transketolase in the immunotherapy and prognosis of hepatocellular carcinoma: A multi-omics approach[J]. Front Immunol, 2025, 16: 1529029. doi: 10.3389/fimmu.2025.1529029. eCollection 2025.
[23]	Gu L, Zhu Y, Nandi SP, et al. FBP1 controls liver cancer evolution from senescent MASH hepatocytes[J]. Nature, 2025, 637(8045): 461-469. doi: 10.1038/s41586-024-08317-9. Epub 2025 Jan 1.
[24]	Gou D, Liu R, Shan X, et al. Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression[J]. J Clin Invest, 2023, 133(13): e161713. doi: 10.1172/JCI161713.
[25]	Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer[J]. Br J Cancer, 2020, 122(1): 4-22. doi: 10.1038/s41416-019-0650-z. Epub 2019 Dec 10.
[26]	Pan B, Chen S, Wu H, et al. Short-term starvation inhibits CD36 N-glycosylation and downregulates USP7 UFMylation to alleviate RBPJ-maintained T cell exhaustion in liver cancer[J]. Theranostics, 2025, 15(12): 5931-5952. doi: 10.7150/thno.110567. eCollection 2025. pmid: 40365281
[27]	Cyriac R, Lee K. Glutaminase inhibition as potential cancer therapeutics: Current status and future applications[J]. J Enzyme Inhib Med Chem, 2024, 39(1): 2290911. doi: 10.1080/14756366.2023.2290911. Epub 2023 Dec 11.
[28]	Su F, Koeberle A. Regulation and targeting of SREBP-1 in hepatocellular carcinoma[J]. Cancer Metastasis Rev, 2024, 43(2): 673-708. doi: 10.1007/s10555-023-10156-5. Epub 2023 Dec 1.
[29]	林叶昕, 陈科, 安方梅, 等. 肝细胞癌患者脂代谢异常分析及脂肪酸结合蛋白的表达意义研究[J]. 中华肝脏病杂志, 2021, 29(10): 1006-1013. doi: 10.3760/cma.j.cn501113-20200416-00189.
[30]	Liu Y, Wang F, Yan G, et al. CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer[J]. Cancer Lett, 2024, 595: 217006. doi: 10.1016/j.canlet.2024.217006. Epub 2024 May 31.
[31]	Yu HC, Bai L, Jin L, et al. SLC25A35 enhances fatty acid oxidation and mitochondrial biogenesis to promote the carcinogenesis and progression of hepatocellular carcinoma by upregulating PGC-1α[J]. Cell Commun Signal, 2025, 23(1): 130. doi: 10.1186/s12964-025-02109-y.
[32]	Xu M, Xie P, Liu S, et al. LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation[J]. Cancer Lett, 2025, 612: 217469. doi: 10.1016/j.canlet.2025.217469. Epub 2025 Jan 20.
[33]	Matsufuji S, Kitajima Y, Higure K, et al. A HIF-1α inhibitor combined with palmitic acid and L-carnitine treatment can prevent the fat metabolic reprogramming under hypoxia and induce apoptosis in hepatocellular carcinoma cells[J]. Cancer Metab, 2023, 11(1): 25. doi: 10.1186/s40170-023-00328-w. pmid: 38066600
[34]	Liu X, Ren B, Ren J, et al. The significant role of amino acid metabolic reprogramming in cancer[J]. Cell Commun Signal, 2024, 22(1): 380. doi: 10.1186/s12964-024-01760-1. pmid: 39069612
[35]	Ziki RA, Colnot S. Glutamine metabolism, a double agent combating or fuelling hepatocellular carcinoma[J]. JHEP Rep, 2024, 6(5): 101077. doi: 10.1016/j.jhepr.2024.101077. eCollection 2024 May.
[36]	Sun Y, Shen Y, Yan Y, et al. GLS1 promotes lipid metabolism in hepatocellular carcinoma by regulating the PI3K/AKT/mTORC1 signaling pathway through SREBP-1[J]. Am J Transl Res, 2025, 17(4): 2527-2540. doi: 10.62347/ZTGP5030. eCollection 2025.
[37]	Tambay V, Raymond VA, Voisin L, et al. Reprogramming of glutamine amino acid transporters expression and prognostic significance in hepatocellular carcinoma[J]. Int J Mol Sci, 2024, 25(14): 7558. doi: 10.3390/ijms25147558.
[38]	Zhang Q, Wei T, Jin W, et al. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism[J]. J Hepatol, 2024, 80(2): 293-308. doi: 10.1016/j.jhep.2023.10.024. Epub 2023 Oct 30. pmid: 38450598
[39]	Hajaj E, Sciacovelli M, Frezza C, et al. The context-specific roles of urea cycle enzymes in tumorigenesis[J]. Mol Cell, 2021, 81(18): 3749-3759. doi: 10.1016/j.molcel.2021.08.005. Epub 2021 Aug 31. pmid: 34469752
[40]	Mossmann D, Müller C, Park S, et al. Arginine reprograms metabolism in liver cancer via RBM39[J]. Cell, 2023, 186(23): 5068-5083. doi: 10.1016/j.cell.2023.09.011. Epub 2023 Oct 6. pmid: 37804830
[41]	Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma[J]. Hepatology, 2023, 77(5): 1773-1796. doi: 10.1002/hep.32740. Epub 2023 Apr 17.
[42]	Surjan RCT, de Lima TM, de Souza HP, et al. Molecular basis of hyperammonemic encephalopathy in fibrolamellar hepatocellular carcinoma[J]. Cureus, 2023, 15(1): e33750. doi: 10.7759/cureus.33750. eCollection 2023 Jan.
[43]	He L, Cai X, Cheng S, et al. Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma[J]. Oncol Lett, 2019, 17(6): 5030-5038. doi: 10.3892/ol.2019.10174. Epub 2019 Mar 21. pmid: 31186714
[44]	Dong F, He K, Zhang S, et al. SSRI antidepressant citalopram reverses the Warburg effect to inhibit hepatocellular carcinoma by directly targeting GLUT1[J]. Cell Rep, 2024, 43(10): 114818. doi: 10.1016/j.celrep.2024.114818. Epub 2024 Oct 9.
[45]	Hu Y, Xing Y, Fan G, et al. L-arginine combination with 5-fluorouracil inhibit hepatocellular carcinoma cells through suppressing iNOS/NO/AKT-mediated glycolysis[J]. Front Pharmacol, 2024, 15: 1391636. doi: 10.3389/fphar.2024.1391636. eCollection 2024.
[46]	Zhong W, Chen T, Chen L, et al. Crippled hepatocarcinogenesis inhibition of quercetin in glycolysis pathway with hepatic farnesoid X receptor deficiency[J]. Curr Pharm Des, 2025, 31(22): 1800-1815. doi: 10.2174/0113816128342642250111055339.
[47]	Lin C, Wan Y, Huo Q, et al. Chemoproteomics reveals Ailanthone directly binds to PKM2 to inhibit the progression of hepatocellular carcinoma[J]. Phytomedicine, 2025, 143: 156886. doi: 10.1016/j.phymed.2025.156886. Epub 2025 May 21.
[48]	Fei M, Li X, Liang S, et al. LncRNA PWRN1 inhibits the progression of hepatocellular carcinoma by activating PKM2 activity[J]. Cancer Lett, 2024, 584: 216620.doi: 10.1016/j.canlet.2024.216620. Epub 2024 Jan 11.
[49]	Li X, Peng X, Li Y, et al. Glutamine addiction in tumor cell: Oncogene regulation and clinical treatment[J]. Cell Commun Signal, 2024, 22(1): 12. doi: 10.1186/s12964-023-01449-x. pmid: 38172980
[50]	Gallage S, Ali A, Barragan Avila JE, et al. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1[J]. Cell Metab, 2024, 36(6): 1371-1393. doi: 10.1016/j.cmet.2024.04.015. Epub 2024 May 7.
[51]	Huang J, Tsang WY, Fang XN, et al. FASN inhibition decreases MHC-I degradation and synergizes with PD-L1 checkpoint blockade in hepatocellular carcinoma[J]. Cancer Res, 2024, 84(6): 855-871. doi: 10.1158/0008-5472.CAN-23-0966. pmid: 38486485
[52]	Chang W, Wang J, You Y, et al. Triptolide reduces neoplastic progression in hepatocellular carcinoma by downregulating the lipid lipase signaling pathway[J]. Cancers (Basel), 2024, 16(3): 550. doi: 10.3390/cancers16030550.
[53]	Tu DY, Peng R, Jin SJ, et al. MARCH8 suppresses hepatocellular carcinoma by promoting SREBP1 degradation and modulating fatty acid de novo synthesis[J]. Cell Death Dis, 2025, 16(1): 391. doi: 10.1038/s41419-025-07707-9.
[54]	He W, Wang M, Zhang X, et al. Estrogen induces LCAT to maintain cholesterol homeostasis and suppress hepatocellular carcinoma development[J]. Cancer Res, 2024, 84(15): 2417-2431. doi: 10.1158/0008-5472.CAN-23-3966.
[55]	Tzeng SF, Yu YR, Park J, et al. PLT012, a humanized CD36-blocking antibody, is effective for unleashing antitumor immunity against liver cancer and liver metastasis[J]. Cancer Discov, 2025, 15(8): 1676-1696. doi: 10.1158/2159-8290.CD-24-1409.
[56]	Ren M, Xu H, Xia H, et al. Simultaneously targeting SOAT1 and CPT1A ameliorates hepatocellular carcinoma by disrupting lipid homeostasis[J]. Cell Death Discov, 2021, 7(1): 125. doi: 10.1038/s41420-021-00504-1. pmid: 34052835
[57]	Liu Z, You Y, Chen Q, et al. Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis[J]. Mol Ther, 2022, 30(2): 606-620. doi: 10.1016/j.ymthe.2021.07.015. Epub 2021 Oct 1.
[58]	Ghosh A, Ghosh AK, Zaman A, et al. Metformin-loaded hyaluronic acid-derived carbon dots for targeted therapy against hepatocellular carcinoma by glutamine metabolic reprogramming[J]. Mol Pharm, 2023, 20(12): 6391-6406.doi: 10.1021/acs.molpharmaceut.3c00772. Epub 2023 Nov 7.
[59]	Prasad YR, Anakha J, Pande AH. Treating liver cancer through arginine depletion[J]. Drug Discov Today, 2024, 29(4): 103940.doi: 10.1016/j.drudis.2024.103940. Epub 2024 Mar 6.
[60]	Li A, Cui H, Zhao E. Targeting RNA-binding motif protein 39 for arginine reduction: unveiling metabolic vulnerability in arginine-dependent liver cancer[J]. MedComm (2020), 2024, 5(7): e581. doi: 10.1002/mco2.581. eCollection 2024 Jul.
[61]	Ning M, Zhu Y, Miao R, et al. A biomimetic nanomedicine for remodeling the immune microenvironment to potentiating anti-tumor therapy[J]. Adv Healthc Mater, 2025: e2501457. doi: 10.1002/adhm.202501457. Epub 2025 Jun 30.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 61

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2024, 39(6): 563-567.
[2]	Li Ya, Du Taoming, Qiu Shixiang, Chen Chao, Zhong Liming. Study on brain functional connectivity in patients with liver cancer with depression [J]. Clinical Focus, 2023, 38(6): 532-536.
[3]	. [J]. Clinical Focus, 2023, 38(5): 473-476.
[4]	Li Ya, Qiu Shixiang, Chen Chao, Zhong Liming. Depression-related factors and corresponding correlations with quality of life in patients with hepatocellular carcinoma [J]. Clinical Focus, 2022, 37(6): 539-543.
[5]	Guo Xiaojun, Kong Yanliang, Liu Tao, Cheng Zhengxiang, Zhang Rui, Fan Lei. CT-guided percutaneous radiofrequency ablation for hepatic carcinoma [J]. Clinical Focus, 2021, 36(9): 807-810.
[6]	Xie Zhihai, Zhou Zhicong, Gui Yuan, Sun Jingfeng. Differential expression of IGF1R antisense noncoding RNA in hepatocellular carcinoma [J]. Clinical Focus, 2021, 36(7): 620-622.
[7]	Liu Huimin,Liu Ping. Study on using ROC curve evaluation of α-L-fucosidase, 5'-nucleo tidase and alpha fetoprotein diagnostic and predictive value in hepatocellular carcinoma [J]. Clinical Focus, 2016, 31(4): 414-417.
[8]	Gu Tao;Liu Lijie;Meng Wei;Hua Haixia;Zhang Yunjie;Zhang Qiuli. Level and significance of circulating histones in patients with hepatocellular carcinoma treated by radiofrequency ablation [J]. Clinical Focus, 2015, 30(12): 1386-1389.
[9]	Zhang Zhiyong;Zhang Qian. Change and clinical significance of serum microRNA-106b expression in hepatocarcinoma patients after transcatheter hepatic arterial chemoembolization [J]. Clinical Focus, 2015, 30(12): 1390-1.39214e+007.
[10]	Zheng Jianxiao;Wu Jinming. Effect of Fuzhengbuxu decotion on T cell subsets and angiogenesis related factors of patients with primary hepatic carcinoma [J]. Clinical Focus, 2015, 30(9): 1036-1038.
[11]	YANG Shou-ping;LI Hai-ying;ZHANG Li. Diagnostic value of combined detection of soluble human leukocyte antigen-G, alpha fetoprotein and alpha fetoprotein-L3 in primary hepatocellular carcinoma [J]. Clinical Focus, 2014, 29(8): 888-890891.
[12]	. [J]. Clinical Focus, 2014, 29(6): 691-691.
[13]	YUAN Su-yun;LAN Tao;ZHOU Guo-qing;WANG Gui-hua;LI Zhi-juan. Effects of ubenimex capsules on serum levels of vascular endothelial growth factors in primary liver carcinoma [J]. CLINICAL FOCUS, 2014, 29(3): 318-320.
[14]	LI Li;LIU Li-feng;WU Yan-ning;LI Qing;CHEN De-xi. Mutation research of c-myc gene in hepatocellular carcinoma [J]. CLINICAL FOCUS, 2013, 28(9): 976-978.
[15]	. [J]. Clinical Focus, 2013, 28(4): 431-432.